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The media reports that American medical care is high quality but too costly and not available to all. The successes in quality and the failures in costs are both attributed to dramatic technologic advances.
The costs are also attributed to rising public demands for care. The political will to adopt sweeping legislation has waxed and waned. However, there is a broad-based, business-initiated stimulus to develop a more rational healthcare delivery system. These concerns about quality, cost, and delivery system sound like contemporary 1994 debates. However, they were presented in 1970
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an increased expectation for accountability by providers and payors for quality and cost. Improved outcome information is needed to meet this expectation of accountability.
Quality, Access, Cost, and Uncertainty Eddy (2) to faulty decision making. To rebuild confidence in the healthcare delivery system, we must insist on quantitative information about actual benefits (9) . This means collecting outcome data.
Government and Marketplace Responses
Early 1994 brought attention to managed competition as a purchasing strategy to maximize public value in healthcare delivery (10) . The competition was to be based on rational microeconomics by using measured outcomes in units of dollars, quality, and satisfaction. The successfiil providers would be rewarded with more customers. The sponsoring payors would be able topool more customers and distribute risks. Businesses suggest that incentives in healthcare are Teisberg et al. (11) further suggest that competition can preserve existing quality and deliver better value if innovation is encouraged and incentives realigned. (14) . These findings suggest barriers to care that should be considered in any healthcare policy decision. Risks must be recognized and incentives must be carefully designed if managed care is to yield good societal outcomes in addition to benefits for a specific subgroup.
The proponents of managed competition suggest that managed care has failed to contain costs (15) . Medical inflation has not slowed, but optimism seems justified that 1994 medical inflation will be less. The lack of quantitative comparative quality and outcome information is one reason why managed care may not be containing costs as hoped (15) .
Transitions

Marketplace
and government responses to uncertainty and to the desires for quality, access, and reduced cost are creating many transitions in the healthcare environment (see Table 1 ).
Process orientation.
Laboratory medicine must be seen as a part of the total process of care. Analysis must be viewed as part of the process of laboratory medicine care. We must maintain expertise in the activities on the perimeter of Fig. 1 while increasing our ability to focus those activities on the final outcomes.
Outcome orientation. Health outcomes are complex. We have an explosion of data (16), but we need increas- (18, 19) . Laboratorians need to assess the contribution of laboratory care to these general measures as well as to study the impact on more specific outcomes.
Two coworkers and I recently studied the effectiveness of a gentamicin dosing and monitoring protocol built on collaboration among physicians, nurses, pharmacists, and laboratorians (20) . We hypothesized that local data would confirm literature data and indicate that higher gentamicin peaks were associated with higher survival rates from gram-negative bacteremia. The protocol encouraged physicians to order gentamicin doses of 2 mg/kg body wt., which was expected to yield peak concentrations near 8 mg/L, if the patient's volume of distribution was near the average of 0.25 11kg. The first dose was monitored, and patient-specific pharmacokinetic data were used to guide future doses and intervals to maintain peak concentrations of 8 ± 2 mgfL, with trough concentrations near 1 mgfL. Monitoring was repeated on alternate days to assure appropriate concentrations.
Consecutive patients with blood culture-positive, gram-negative bacteremia were studied retrospectively. Table 2 shows that higher initial aminoglycoside peak concentration is nearly monotonically associated with higher survival frequencies.
Review of results from the 36 more severely ill patients (with classified severity of 3 or 4 by the MEDISGROUPS system) (21) showed that if the initial and average gentamicin peak concentrations were >6 mg/L, 18 of 20 (90%) survived; if these concentrations were not achieved, only 8 of 16 (50%) survived. We concluded that our program confirmed literature data, and higher peak concentrations improved outcomes. Laboratorians need to focus attention on outcomes (Fig. 1) .
Consumer
orientation.
The (Fig. 2) . To achieve the ideals of Fig. 2 , we must postpone the onset of chronic diseases. Death is not preventable, but it may be postponable.
Physiological decline is also not preventable but postponable. Fries implies that societal healthcare costs will be increased by lengthening survival if chronic diseases cannot be postponed. That is, lengthening life without postponing the onset of chronic disease lengthens the period of time in physiological decline (Fig. 3B) .
In the past, healthcare was characterized by what I call "piecework profit." Providers were financially rewarded for providing specific care events, and rewards were increased if care was efficient. The future system will focus on prevention (i.e., postponement of morbidity), and financial rewards will accrue from improved health status in a population because services will not be needed (i.e., prevention profit).
We have studied outcomes among well individuals presenting for laboratory tests in public health fairs and voluntary employee groups (30, 31) . These data indicate that sensitive thyrotropin (TSH) measurements provided to ambulatory well individuals will identify a new diagnosis in 1.2% and initiate a change in therapy in 1.1% (see Table 3 ). If the incremental cost of adding TSH to this testing activity is $2, the cost per benefited participant is calculated as $2000 to test 1000 people, benefiting 23 ($2000 ± 23 = $87 per benefit). If the total charge for the whole testing program (including many tests) is $25 per individual, the charge per benefit is $25 000/23 or $1087 per benefit. Of course, the program may readily provide benefits in addition to those attributed to TSH, which would affect these calculations (30) . Nonetheless, we have an obligation to understand the costs for benefits attributable to laboratory tests.
Cost of production orientation. Healthcare must be understood from both the macroeconomic and micro- economic perspective. We all hear discussions such as, "we found a way to get some of our patients out of the hospital a little earlier; we move them from an acutecare bed over to this hotel sort of function, and we save $400/day per person." The charge for that hospital day was $400; a hospital day did not occur. Someone did not pay the hospital that $400, or that $400 did not appear on the charge ledger. But did the hospital actually save $400? Of course not; the $400 charge was made up of allocations for debt, building and administration, and profit plus the cost of care. Only direct costs were saved. Those allocations need to be paid. In a micro sense, charge is a very poor proxy for cost (32, 33 
Centralization?
There is a paradox. Healthcare institutions are seeking wider and wider mergers, while individuals attempt to retain personal choices. In the laboratory, we see mergers and simultaneous movements toward point-of-care testing. Are these trends, in fact, internally consistent? That arrow remains twoheaded in Table 1 . In which direction is this transition moving?
Outcome Data Needed
The need for outcome data is the recurring theme when considering the forces and proposed solutions for the American healthcare question. When contributions in such diverse publications as Healthcare Forum (37) and Science (38) call for healthcare outcomes information, outcomes data must be important.
Not all seem satisfied with this new ascendancy of statistical outcome data (39) . We must remember that society will probably receive real-world "effectiveness" of procedures, which is less than the maximal potential "efficacy" observed in controlled clinical trials. Tanenbaum (39) states the case for clinical judgment.
Has the trend toward outcomes assessment already overtaken the autonomous provider?
Laboratorians need to participate in assessing outcomes. Benefits attributable to laboratory procedures need to be identified. We must maximize the value we provide to others and not try to merely protect our turf. Has the theory of the laboratory business (40) moved to a new paradigm?
Healthcare is evolving. We are advancing past eventdriven cost-avoidance mechanisms, such as utilization review, and into value improvement philosophies, such as total quality management, reengineering, and outcomes monitoring.
When will the next evolutionary step occur? Will it be the movement toward healthier populations?
Fries' hypothesis (29) suggests that the healthier population focus is necessary.
The evolutionary process in healthcare causes an ever-increasing accountability for costs and quality. This means we need better outcomes data now.
R.D. Schrantz and D.L. Wegner provided expert analysis for the data in Table 2 .
